


# สถานการณ์เชื่อด้อย่าต้านจุดชีพ ปี 2000-2020(12M)

ศูนย์เฝ้าระวังเชื่อด้อย่าต้านจุดชีพแห่งชาติ (NARST)  
สถาบันวิจัยวิทยาศาสตร์สาธารณสุข กรมวิทยาศาสตร์การแพทย์


<http://narst.dmsc.moph.go.th>

# Antimicrobial Resistance rates of *Enterococcus* spp. by year

## (NARST - 56 hospitals, 12M 2020)




# Rate of vancomycin resistant enterococci




# Percent resistance of *E. faecium*, *E. faecalis* to vancomycin


## *E. faecium*





## *E. faecalis*



# Antimicrobial Resistance rates of *Staphylococcus spp.* by year (NARST - 56 hospitals, 12M 2020)




# Percent isolates of Methicillin Resistance *S. aureus* (MRSA) and Methicillin Resistance *Staphylococcus* coagulase negative (MRSCN)




# Antimicrobial Resistance rates of *S. pneumoniae* by year

## (NARST - 56 hospitals, 12M 2020)




# Susceptibility of *S. pneumoniae* by specimen

## Penicillin G (Oxacillin)




## Erythromycin





# Antimicrobial Resistance rates of *Acinetobacter* spp. by year

## (NARST - 56 hospitals, 12M 2020)




12M 2020 56H

NARST data

# Antimicrobial Resistance rates of *P. aeruginosa* by year (NARST - 56 hospitals, 12M 2020)

- Piperacillin/Tazobactam
- Ceftazidime
- Imipenem
- Norfloxacin (UTI)
- Ciprofloxacin
- Amikacin
- Colistin (MIC)




12M 2020 56H

NARST data


CLSI 2019 ไม่กำหนดให้วาง Norfloxacin

# Carbapenem Resistance in *Acinetobacter* spp. and *Pseudomonas aeruginosa*


## *Acinetobacter* spp.




## *Pseudomonas aeruginosa*



# Rate of Imipenem Resistant *Acinetobacter* spp.




% R




*Acinetobacter* spp.  
all species

# Percent resistance of *A. calcoaceticus*-*baumannii* complex to Imipenem




# Antimicrobial Resistance rates of *E. coli* by year (NARST - 56 hospitals, 12M 2020)



12M 2020 56H

NARST data

# Antimicrobial Resistance rates of *K. pneumoniae* by year (NARST - 56 hospitals, 12M 2020)




12M 2020 56H

NARST data

# ESBL producing *E. coli*


Cefotaxime  $R_{\leq 27}$

■ ESBL by screen test



Ceftazidime  $R_{\leq 22}$

■ ESBL by screen test






# ESBL producing *K. pneumoniae*


## Cefotaxime R<sub>≤27</sub>

■ ESBL by screen test




## Ceftazidime R<sub>≤22</sub>


■ ESBL by screen test




# Percentage Resistance of *E. coli* and *K. pneumoniae*



# Carbapenem Resistance in *E. coli* and *K. pneumoniae*



# Percent resistant of **Non-typhoidal Salmonella** isolated from **Blood**, 2000-2020 (12M)



# Percent resistant of *Non-typhoidal Salmonella* isolated from **Stool & Rectal swab**, 2000-2020 (6M)

%R

